Drug Evaluation Data

Singer F. : Treatment of Paget's Disease of Bone, Postgrad. Med. 57: 117–120 (Mar.) 1975.

Munson P. : Thyrocalcitonin: Physiological Importance and Significance in Renal Failure, Am. J. Med. Sci. 262: 310–319 (Dec.) 1971.

Schumacher C. : Paget's Disease of Bone, Arch. Intern. Med. 131: 722–724 (May) 1973.

Editorial: Calcitonin in the Treatment of Paget's Disease of Bone. Ann. Intern. Med. 76: 665–666 (Apr.) 1972.

Singer F. : Current Concepts of Bone Metabolism, Ann. Intern. Med. 80: 633–644 (May) 1974.

Moffatt W. : Effects of Calcitonin Therapy in Deafness Associated With Paget's Disease of Bone, Br. Med. J. 2: 203 (Oct. 26) 1974.

Hamilton C. : Effects of Synthetic Salmon Calcitonin in Patients With Paget's Disease of Bone, Am. J. Med. 56: 315–322 (Mar.) 1974.

Berggvist E. : Calcitonin in the Treatment of Hypercalcemic Crisis, Acta Med. Scand. 192: 385–389, 1972.

Silva O. : Salmon Calcitonin in the Treatment of Hypercalcemia, Arch. Intern. Med. 132: 337–339 (Sept.) 1973.

Silva O. : Salmon Calcitonin is Effective in Combating Hypercalcemia, Geriatrics 28: 178–181 (Oct.) 1973.

Vaughn C. : The Effects of Calcitonin in Hypercalcemia in Patients With Malignancy, Cancer 34: 1268–1271, 1974.

Brodier P. : Effectiveness of Parathyroid Hormone, Calcitonin, and Phosphate on Bone Cells in Paget's Disease, Am. J. Med. 56: 850–857 (June) 1974.

Krane S. : Acute Effects of Calcitonin in Bone Formation in Man, Metabolism 22: 51–58 (Jan.) 1973.

Deftar L. : Medical Management of the Hypercalcemia of Malignancy, Ann. Rev. Med. 25: 323–331, 1974.

Haas H. : Renal Effects of Calcitonin and Parathyroid Extract in Man, J. Clin. Invest. 50: 2689–2702, 1971.

Burckhardt P. M. : Parathyroid Function in Patients With Paget's Disease Treated With Salmon Calcitonin, Clin. Endo. 2: 15–22 (Jan.) 1973.

Foster G. V. : Effects of Thyrocalcitonin in Man, Lancet 1: 107–109 (Jan. 15) 1966.

Potts J. T. : Calcitonin, Curr. Topics Exper. Endocronol. 3: 151–173, 1971.

Haddad J. : Calcitonin Resistance: Clinical and Immunologic Studies in Subjects With Paget's Disease of Bone Treated With Porcine and Salmon Calcitonins, J. Clin. Invest. 51: 3133–3141 (Dec.) 1972.

Galante L. : The Calcium Lowering Effect of Synthetic Human, Porcine, and Salmon Calcitonin in Patients With Paget's Disease, Clin. Sci. 44: 605–610 (June) 1973.

Dube W. : Development of Antibodies to Porcine Calcitonin During Treatment of Paget's Disease of Bone, Mayo Clin. Proc. 48: 43–45 (Jan.) 1973.

Singer F. : An Evaluation of Antibodies and Clinical Resistance to Salmon Calcitonin, J. Clin. Invest. 51: 2331–2338 (Sept.) 1972.

Haddad J. : Paget's Disease of Bone: Problems and Management, Orthopedic Clin. of N.A. 3: 775–786 (Nov.) 1972.

DeRose J. : Response of Paget's Disease to Porcine and Salmon Calcitonins, Am. J. Med. 56: 858–866 (June) 1974.

Personal Communication — Frederick R. Singer, USC-LA County Medical Center.

Kammerman S. : New Modes of Therapy For Paget's Disease of Bone, Am. J. Med. Sci. 263: 393–395 (May) 1972.

Singer F. : Inactivation of Calcitonin by Specific Organs. Nature New Biology 237: 269–270 (June 28) 1972.